|
Jun 23
|
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
|
|
Jun 21
|
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
|
|
Jun 21
|
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
|
Jun 21
|
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
|
|
Jun 14
|
Takeda signs option agreement with Ascentage for CML drug
|
|
Jun 14
|
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug
|
|
Jun 14
|
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
|
|
Jun 14
|
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
|
|
Jun 11
|
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
|
|
May 14
|
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
|
May 14
|
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
|
|
May 14
|
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
|
|
May 13
|
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
|
|
May 13
|
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
|
|
May 13
|
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
|
|
May 13
|
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
|
|
May 10
|
Catalyst's New CEO Has Big Ideas For The Small Biotech
|
|
May 9
|
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
|
|
May 9
|
Takeda tackles $900m restructuring plan after generics hurt annual profits
|
|
May 9
|
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
|